胰岛素增敏剂与ACEI类药物治疗胰岛素抵抗的研究进展

Research progress of insulin sensitizers and ACEI drugs in thetreatment of insulin resistance

胰岛素抵抗(IR)见于2型糖尿病(T2DM)、高脂血症、非酒精性脂肪肝(NAFLD)、高血压等诸多疾病的发病过程中,也是代谢综合征(MS)的组成部分和重要发病机制,改善IR对代谢性疾病的治疗有积极的促进作用。本文通过收集近年关于改善IR的临床报道,从胰岛素增敏剂、ACEI/ARB两方面对其改善IR的机制与研究报道进行综述。

Insulin resistance （IR）cxists in the process of type 2 diabetes mellitus （T2DM）, hyperlipidemia, nonalcoholic fatty liver disease （NAFLD）, hypertension and many other diseases,and it＇s also the important component and pathogenesis of metabolic syndrome （MS）. Improvement of IR on metabolic diseases will lead a positive role in the clinical treatment. In this paper,the improvement mechanism and clinical research of insulin sensitizer and ACEI/ARB working on IR will be reviewed,through the collection of clinical reports on the improvement of IR in recent years.